ArticleIntegrative medicine research2025
Modified Saengmaeksan, an herbal formula containing six herbs, improves hypertension through RhoA/Rho kinase-mediated vasorelaxation.
Article in Integrative medicine research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Saengmaeksan is a traditional herbal formula used in Korean medicine. We composed a modified formula based on Saengmaeksan (mSMS) with Puerariae Radix, Platycodonis Radix, Liriopis seu Ophiopogonis Tuber, Schisandrae Fructus, Coicis Semen, and Dioscoreae Rhizoma to investigate its in vivo and ex vivo antihypertensive effects and underlying mechanisms. Methods: The antihypertensive efficacy of mSMS was assessed using l-NAME-induced hypertensive mice and spontaneously hypertensive rats (SHR). The animals were treated with mSMS, and blood pressure was monitored weekly. Vascular effects were evaluated through organ bath studies and aortic histology, while oxidative stress was assessed using DCF-DA staining. Renal protection was examined via H&E and immunofluorescence staining for AT1R expression. The molecular mechanisms were explored through Western blot analysis and GTP-RhoA assays. Results: mSMS significantly reduced systolic and diastolic blood pressure in both hypertensive models, with the ethanol extract demonstrating superior efficacy. mSMS inhibited the RhoA/Rho kinase pathway, leading to reduced phosphorylation of MYPT1 and CPI17, and improved vascular relaxation. Additionally, mSMS attenuated aortic wall thickening, oxidative stress, and renal damage, with a marked decrease in AT1R expression in the kidneys. Conclusions: mSMS exhibits potent antihypertensive effects through the inhibition of the RhoA/Rho-kinase pathway, reduction of vascular remodeling, oxidative stress, and renal protection. These findings support the potential of mSMS as a novel therapeutic agent for hypertension, offering a multi-targeted approach with fewer side effects compared to conventional therapies. Further clinical studies are required to confirm its clinical efficacy.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.